NCT03961334

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 620 (estimated)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) within 7 days of symptom onset versus standard of care (antiplatelet) as preventive treatment.

Detailed description

Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible patients will be randomly assigned to either the standard of care (control) or the experimental (direct start with DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up period within one year after index stroke.

Conditions

• Stroke, Ischemic

Interventions

Type	Name	Description
DRUG	Dabigatran	150mg 2x/d
DRUG	Apixaban	5mg 2x/d
DRUG	Edoxaban	60mg 1x/d
DRUG	Aspirin	100mg 1x/d
DRUG	Clopidogrel	75mg 1x/d

Timeline

• Start date: 2019-12-05
• Primary completion: 2025-01-31
• Completion: 2026-01-31
• First posted: 2019-05-23
• Last updated: 2023-08-16

Locations

14 sites across 5 countries: Greece, Norway, Spain, Switzerland, United Kingdom